Acta Haematologica · 1999 · 18 citations · 26 references
MedicineHematologyHematology PhysiologyHemostasisPediatric HematologyBleeding DisordersCoagulation AbnormalitiesCoagulation DisordersCoagulation Factor DeficienciesCoagulation PhysiologyHemostatic DisordersCoagulation Factor Replacement TherapyFactor Viii ActivationFactor Viii ReplacementFactor Viiia ComplexInhibitor Screening
In 58 hemophilia A patients aged 1-18 years (mean 9.5 +/- 4.7 years), the prevalence of inhibitors was found to be 27% by the Bethesda method in November 1995. Inhibitor activity was not detected in any of 14 patients with mild hemophilia while it was present in 9 of 27 (33%) patients with moderate, and 7 of 17 (41%) with severe disease. During follow-up, the inhibitors were transient in 10 of 16 patients (17%) and the prevalence of inhibitors was 10% at the end of the study. Our study has demonstrated that the patients' age, factor VIII (F VIII) coagulant activity levels, type of F VIII replacement therapy, and frequency of F VIII administration affect inhibitor development, and these factors should be considered in the follow-up of hemophiliacs.
26
Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
S. Ehrenforth, W. Kreuz, R. Linde et al. · The Lancet · 1992 · 608 citations
Medicine, Hematology, Hemostasis +11
Acquired inhibitors of blood coagulation.
DI Feinstein, Samuel I. Rapaport · PubMed · 1972 · 519 citations
Medicine, Hematology, Hemostasis +9
Jeanne M. Lusher, Steven Arkin, Charles F. Abildgaard et al. · New England Journal of Medicine · 1993 · 494 citations · Full text